May 13, 2024 07:39 AM EDTUpdated 01:20 PM
R&D

Mer­ck winds down Phase 3 TIG­IT/PD-1 com­bo study due to safe­ty-re­lat­ed dropouts

Ayisha Sharma

News Reporter

A large num­ber of pa­tient dropouts caused by im­mune side ef­fects have forced Mer­ck to end a late-stage tri­al of its an­ti-TIG­IT drug vi­bostolimab in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times